Table 5.

LNG-IUS 13.5mg vs. SARC, base case results

	LNG-IUS 13.5mg	SARC	Increment
Total cost ($)	$1,283,479	$1,862,633	($579,154)
Drug acquisition	$650,320	$943,956	($293,636)
Medical resource use	$415,810	$215,481	$200,330
Failure (UP)	$14,026	$299,784	($285,758)
Subsequent method1	$203,322	$403,412	($200,089)
UP	64	276	(212)
ICER ($/UP avoided)			Dominant

¹Summation of drug acquisition costs, medical resource use costs and failure costs resulting from use of the subsequent method.